These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation. Du J; Liu J; Gu J; Zhu P Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570 [TBL] [Abstract][Full Text] [Related]
45. Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. Uchino M; Ogawa Y; Uchino Y; Mori T; Okamoto S; Tsubota K Br J Ophthalmol; 2012 Jan; 96(1):34-7. PubMed ID: 22053104 [TBL] [Abstract][Full Text] [Related]
46. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150 [TBL] [Abstract][Full Text] [Related]
47. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
48. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313 [TBL] [Abstract][Full Text] [Related]
49. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Mikulska M; Raiola AM; Bruno B; Furfaro E; Van Lint MT; Bregante S; Ibatici A; Del Bono V; Bacigalupo A; Viscoli C Bone Marrow Transplant; 2009 Sep; 44(6):361-70. PubMed ID: 19308042 [TBL] [Abstract][Full Text] [Related]
50. Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. Hauzenberger D; Schaffer M; Ringdén O; Hassan Z; Omazic B; Mattsson J; Wikström AC; Remberger M Tissue Antigens; 2008 Dec; 72(6):549-58. PubMed ID: 19000143 [TBL] [Abstract][Full Text] [Related]
51. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors? Ruggeri A; Ciceri F; Gluckman E; Labopin M; Rocha V; Best Pract Res Clin Haematol; 2010 Jun; 23(2):207-16. PubMed ID: 20837332 [TBL] [Abstract][Full Text] [Related]
52. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Ljungman P; Brand R; Hoek J; de la Camara R; Cordonnier C; Einsele H; Styczynski J; Ward KN; Cesaro S; Clin Infect Dis; 2014 Aug; 59(4):473-81. PubMed ID: 24850801 [TBL] [Abstract][Full Text] [Related]
53. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339 [TBL] [Abstract][Full Text] [Related]
54. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Mabilangan C; Preiksaitis JK; Cervera C; Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023 [TBL] [Abstract][Full Text] [Related]
55. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Mabilangan C; Preiksaitis J; Cervera C; Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174 [TBL] [Abstract][Full Text] [Related]
56. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes. Corrales I; Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; Garcia-Noblejas A; Navarro D J Med Virol; 2015 Feb; 87(2):248-55. PubMed ID: 25132583 [TBL] [Abstract][Full Text] [Related]
57. Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). Martino R; Bautista G; Parody R; García I; Esquirol A; Rovira M; Cabrera JR; Regidor C; Fores R; García-Marco JA; Serrano D; Barba P; Heras I; Marquez-Malaver FJ; Sánchez-Ortega I; Duarte R; Saavedra S; Sierra J; Vazquez L; Transpl Infect Dis; 2015 Apr; 17(2):221-33. PubMed ID: 25652036 [TBL] [Abstract][Full Text] [Related]
58. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients. Florescu DF; Langnas AN; Grant W; Mercer DF; Botha J; Qiu F; Shafer L; Kalil AC Pediatr Transplant; 2012 May; 16(3):294-301. PubMed ID: 22212495 [TBL] [Abstract][Full Text] [Related]